Genetic and epigenetic profiling as search engines to select BRCA-deficient tumors sensitive to synthetic lethality by targeting RAD52. Genetic profiling will identify patients with tumors harboring BRCA1/2 mutations or expressing oncogenes (such as BCR-ABL1 and PML-RAR) that directly or indirectly cause genetic BRCA deficiency. Gene expression profiling by microarray analysis or qPCR should select individual patients with tumors displaying epigenetic BRCA-deficient phenotype.